Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
May 16, 2024 20:02 ET
|
Erasca, Inc.
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce...
Carbon Streaming Announces Further Update on Rimba Raya Project
May 15, 2024 21:30 ET
|
Carbon Streaming Corporation
Carbon Streaming Announces Further Update On Rimba Raya Project
Irish Continental Group plc (ICG) subsidiary Irish Ferries signs space charter agreement with P&O Ferries
May 15, 2024 10:57 ET
|
Irish Continental Group Plc
ICG is pleased to announce that its subsidiary Irish Ferries has signed a space charter agreement with P&O Ferries on the Dover – Calais route. This agreement will encompass both freight and...
Pacific Software Inc. Secures Strategic License Agreement with the University of California for Innovative Technology for Stimulating Collagen Production
May 15, 2024 09:00 ET
|
Pacific Software Inc.
Pacific Software Inc. partners with UCI to launch Dermatrix™, a revolutionary collagen-boosting peptide for cosmetics and wound healing.
Interfield Global Software Inc. Announces Execution of Definitive License Agreement With JRL Energy Inc.
May 14, 2024 17:00 ET
|
Interfield Global Software Inc.
NOT FOR DISTRIBUTION TO THE UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW. ...
アディア (Adeia) が三菱電機とのライ センスを更新
May 14, 2024 08:30 ET
|
Adeia Inc.
カリフォルニア州サンノゼ発, May 14, 2024 (GLOBE NEWSWIRE) -- 特許取 得済みのイノベーションを駆使し、世界がエンターテインメントを探求･体験す る方法を形作るアディア (NASDAQ:ADEA) は本日、日本の多国籍電子・電気 機器メーカーである三菱電機がアディアのメディア知的財産 (IP) ポートフォリ...
Adeia Enters into License Renewal with Mitsubishi Electric
May 14, 2024 08:30 ET
|
Adeia Inc.
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), the company whose patented innovations shape the way the world explores and experiences entertainment, today announced...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024 07:00 ET
|
Fulcrum Therapeutics, Inc.
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024 06:00 ET
|
Fulcrum Therapeutics, Inc.
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024 06:00 ET
|
AC Immune SA
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights...